These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 22114882

  • 1. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis.
    Zhang X, Peck R.
    Expert Rev Clin Pharmacol; 2011 Sep; 4(5):539-58. PubMed ID: 22114882
    [Abstract] [Full Text] [Related]

  • 2. Humanized antihuman IL-6 receptor antibody, tocilizumab.
    Nishimoto N, Kishimoto T.
    Handb Exp Pharmacol; 2008 Sep; (181):151-60. PubMed ID: 18071945
    [Abstract] [Full Text] [Related]

  • 3. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
    Diaz-Torne C, Ortiz MDA, Moya P, Hernandez MV, Reina D, Castellvi I, De Agustin JJ, Fuente D, Corominas H, Sanmarti R, Zamora C, Cantó E, Vidal S.
    Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
    [Abstract] [Full Text] [Related]

  • 4. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.
    Gibiansky L, Frey N.
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):5-16. PubMed ID: 22101760
    [Abstract] [Full Text] [Related]

  • 5. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy.
    Snir A, Kessel A, Haj T, Rosner I, Slobodin G, Toubi E.
    Clin Exp Rheumatol; 2011 Feb; 29(4):697-700. PubMed ID: 21813064
    [Abstract] [Full Text] [Related]

  • 6. Tocilizumab: A Review in Rheumatoid Arthritis.
    Scott LJ.
    Drugs; 2017 Nov; 77(17):1865-1879. PubMed ID: 29094311
    [Abstract] [Full Text] [Related]

  • 7. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
    Nasonov EL.
    Ter Arkh; 2010 Nov; 82(5):64-71. PubMed ID: 20597275
    [Abstract] [Full Text] [Related]

  • 8. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q, Zhao Y, Bao CD, Li XF, Huang F, Zhu P, Li ZG, Gu JR, Zhang ZY, Zhao DB, Zhao SL, Jiang QD, Tian J, Zhang FC.
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [Abstract] [Full Text] [Related]

  • 9. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.
    June RR, Olsen NJ.
    Expert Opin Biol Ther; 2016 Oct; 16(10):1303-9. PubMed ID: 27464017
    [Abstract] [Full Text] [Related]

  • 10. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG.
    Drug Des Devel Ther; 2017 Oct; 11():1593-1603. PubMed ID: 28579757
    [Abstract] [Full Text] [Related]

  • 11. Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis.
    Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, Hattori K, Kohsaka H, Miyasaka N, Takeuchi T, Naka T.
    Arthritis Rheumatol; 2015 May; 67(8):2056-60. PubMed ID: 25917892
    [Abstract] [Full Text] [Related]

  • 12. Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells.
    Muhammad K, Roll P, Seibold T, Kleinert S, Einsele H, Dörner T, Tony HP.
    Ann Rheum Dis; 2011 Aug; 70(8):1507-10. PubMed ID: 21551509
    [Abstract] [Full Text] [Related]

  • 13. Effect of IL-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type-9 and Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients.
    Ferraz-Amaro I, Hernández-Hernández MV, Tejera-Segura B, Delgado-Frías E, Macía-Díaz M, Machado JD, Diaz-González F.
    Horm Metab Res; 2019 Mar; 51(3):200-209. PubMed ID: 30695794
    [Abstract] [Full Text] [Related]

  • 14. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M, Östör A.
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [Abstract] [Full Text] [Related]

  • 15. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
    Avci AB, Feist E, Burmester GR.
    BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
    [Abstract] [Full Text] [Related]

  • 16. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
    Mitchell E, Jones G.
    Expert Rev Clin Immunol; 2016 Dec; 12(2):103-14. PubMed ID: 26629984
    [Abstract] [Full Text] [Related]

  • 17. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.
    Ducreux J, Durez P, Galant C, Nzeusseu Toukap A, Van den Eynde B, Houssiau FA, Lauwerys BR.
    Arthritis Rheumatol; 2014 Jan; 66(1):15-23. PubMed ID: 24449571
    [Abstract] [Full Text] [Related]

  • 18. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
    Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L, Hemeryck A, Jacobs S, Baumeister J, Ulrichts H.
    Arthritis Res Ther; 2015 May 20; 17(1):135. PubMed ID: 25994180
    [Abstract] [Full Text] [Related]

  • 19. Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.
    Lee EB, Daskalakis N, Xu C, Paccaly A, Miller B, Fleischmann R, Bodrug I, Kivitz A.
    Clin Pharmacokinet; 2017 Jun 20; 56(6):607-615. PubMed ID: 27722854
    [Abstract] [Full Text] [Related]

  • 20. [Tocilizumab in rheumatoid arthritis].
    Rueda Gotor J, Blanco Alonso R.
    Reumatol Clin; 2011 Mar 20; 6S3():S29-32. PubMed ID: 21794769
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.